4//SEC Filing
Gheuens Sarah 4
Accession 0001439222-25-000111
CIK 0001439222other
Filed
Oct 28, 8:00 PM ET
Accepted
Oct 29, 4:02 PM ET
Size
9.1 KB
Accession
0001439222-25-000111
Insider Transaction Report
Form 4
Gheuens Sarah
Chief Medical Officer
Transactions
- Sale
Common stock
2025-10-27$43.92/sh−3,302$145,024→ 61,727 total - Exercise/Conversion
Common stock
2025-10-27$25.01/sh+3,302$82,583→ 65,029 total - Exercise/Conversion
Stock options (right to buy)
2025-10-27−3,302→ 28,784 totalExercise: $25.01Exp: 2033-03-01→ Common stock (3,302 underlying)
Footnotes (4)
- [F1]Includes 456 shares purchased through the Company's employee stock purchase plan.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $43.77 to $44.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001881190
Filing Metadata
- Form type
- 4
- Filed
- Oct 28, 8:00 PM ET
- Accepted
- Oct 29, 4:02 PM ET
- Size
- 9.1 KB